Toujeo now available for UK adults with diabetes

The new once-daily basal insulin Toujeo has become available for clinicians to prescribe in the UK, providing another option for adults with type 1 and type 2 diabetes mellitus to help manage their condition. In trials, Toujeo demonstrated similar glycaemic control with a lower incidence of confirmed hypoglycaemia when compared to Lantus in the treatment of adults with type 2 diabetes. There are currently 3.3 million people in the UK diagnosed with diabetes a figure predicted to rise to an estimated five million people by 2025. More than two thirds of adults treated with insulin do not reach the National